1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This funding opportunity aims to establish the Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Program.
It supports the development of innovative, reliable, cost-effective, and sustainable multimodal AI-based clinical decision support (CDS) tools.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Grants for Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed) | Office of the Vice Chancellor for Research and Innovation (OVCRI) Grants for Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed) Funding & Proposal Support Grants for Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed) Grants for Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed) Direct Link to Opportunity https://files.
simpler. grants. gov/opportunities/5b0a5980-5b84-4cdf-9370-2a36c301760b/attachments/b393021d-fd46-42cb-b1e4-c30273478aad/RFA-RM-27-011-Full-Announcement.
html Up to $300,000/year for 2 years National Institutes of Health
According to the current listing, eligibility includes: Eligible applicants include for-profit organizations other than small businesses, special district governments, state governments, Native American tribal organizations (other than Federally recognized tribal governments…. Confirm the full requirements in the official notice before applying.
The current listing shows $300,000 (Award Ceiling) - $2,000,000 (Estimated Total Program Funding). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed) are due October 9, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article